Thursday, July 17, 2025 7/17/2025

Development of novel isoflavone drugs as broad spectrum antivirals

Award Number: R44AI115824
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/22/2016
PERIOD OF PERFORMANCE END DATE: 12/31/2018

Group Awards By:

View Award Description

Development of novel isoflavone drugs as broad spectrum antivirals - ¿ DESCRIPTION (provided by applicant): Kineta has discovered a novel class of broad spectrum small molecule antivirals that function through a host directed mechanism. These compounds have demonstrated an innovative mechanism of action and target several high priority pathogens that are commercially valuable. The lead chromenone-based candidates have potency in the nM range, inhibit multiple viruses including influenza, coronavirus, West Nile, ebola, and dengue virus in vitro and in animal models, have an attractive pharmacologic profile, and are well tolerated in vivo. In this application, we will perform lead optimization and preclinical development of the lead series. The major milestone of the project is to select one or more nominated drug candidates for formal IND-enabling development towards an oral therapeutic for broad respiratory viral infections. Drug treatment to stimulate the host innate immune response is increasingly appreciated as a strategy for therapeutic intervention and has the potential to redefine the paradigm of antiviral drug development. The need for effective antivirals is great, and our approach to stimulate innate immunity in the presence of diverse viral countermeasures has yielded promising leads that are effective against a broad range of RNA and DNA viruses. We have assembled a highly qualified development team that includes the Kineta scientists responsible for the antiviral discovery work and Prof Michael Gale, Jr. of the University of Washington, an expert in innate immunity and the antiviral response.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2017	KINETA, INC.	219 TERRY AVE N STE 300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	2	3/1/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $789,520 )
2017	2017	KINETA, INC.	219 TERRY AVE N STE 300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	2	5/31/2017	NON-COMPETING CONTINUATION	$746,345
2017	2016	KINETA, INC.	219 TERRY AVE N STE 300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	1	5/25/2017	NEW	$43,175
														Subtotal = $789,520

Issue Date FY: 2016 ( Subtotal = $714,642 )
2016	2016	KINETA INC	307 WESTLAKE AVENUE NORTH	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	1	6/21/2016	NEW	$714,642
														Subtotal = $714,642

Grand Total All Awards = $1,504,162

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of novel isoflavone drugs as broad spectrum antivirals

Award Number: R44AI115824

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/22/2016

PERIOD OF PERFORMANCE END DATE: 12/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer